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Developing and comparing two different prognostic
indexes for predicting disease-free survival of nonmetastatic
breast cancer patients
Zehra Füsun TOKATLI1, Mevlüt TÜRE2, İmran KURT ÖMÜRLÜ2, Ruşen ÇOŞAR ALAS3,
Mustafa Cem UZAL3

Aim: To determine 2 different prognostic indexes (PI) for the differentiation of subgroups of nonmetastatic breast
cancer patients with the Cox regression analysis and survival tree (ST) methods and the additional usage of the KaplanMeier estimates to investigate the predictive power of these methods.
Materials and methods: Prognostic factors data were collected for 410 patients. The Cox regression analysis examines
the relationship of the survival distribution and covariates. The ST method is a tree-structured survival analysis based on
a recursive partitioning algorithm. In this study, Harrell’s concordance indexes of models for training and test sets were
computed. Furthermore, survival curves were estimated by the Kaplan-Meier method. Disease-free survival (DFS) was
calculated from the time of initial diagnosis (initiation of the first treatment) to the first recurrence of disease.
Results: After a median follow-up of 48 months, 100 (24.4%) patients have had at least 1 of the DFS events. In Cox
regression analysis, we proposed the simple PI, which is a sum of axillary nodal and HER2/neu status. In the ST method,
we identified 3 variables: HER2/neu, axillary nodal, and estrogen receptor status. The axillary nodal status was the most
important determining factor for recurrence.
Conclusion: We found that the PI of the ST and Cox regression methods had similar performance levels in predicting
DFS, and the error rates of the models were close to each other in the training and test sets. Furthermore, we determined
that the axillary nodal status and HER2/neu were the most important determining factors for prediction of DFS in
breast cancer patients.
Key words: Breast cancer, survival tree, recursive partitioning, disease-free survival, prognostic index

Nonmetastatik meme kanserli hastalarda hastalıksız sağkalımın belirlenmesinde iki
farklı prognostik indeksin geliştirilmesi ve kıyaslanması
Amaç: Cox regresyon analizi ve recursive partitioning analizine dayanan sağkalım ağacı (ST) ile non-metastatik meme
kanserli hastaların alt gruplara ayrılmasında farklı prognostik indeksler (Pİ) belirlemek ve bu metodların tahmin
güçlerini Kaplan-Meier analizi ile karşılaştırmaktır.
Yöntem ve gereç: Veriler, her bir prognostik faktör için 410 hastadan elde edildi. Cox regresyon analizi, ortak
değişkenlere göre yaşamsal dağılımı inceleyen bir yöntemdir. ST yöntemi ise recursive partitioning algoritmasına
dayanan ağaca yapılı bir sağkalım analizidir. Çalışmada, train ve test setleri için Harrell’ın uyum indeksine göre hata
oranları incelendi. Ayrıca train seti için yaşam eğrileri Kaplan-Meier yöntemi ile tahmin edildi. Hastalıksız sağkalım,
hastalığın ilk tanısından (ilk tedavinin başlangıcından) ilk nüksüne kadar geçen zaman olarak hesaplandı.
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Bulgular: 48 aylık ortanca takip sonrası 100 (% 24,4) hastada hastalıksız sağkalım açısından en az bir olay görüldü. Cox
regresyon analizinde HER2/neu ve aksiller nodal durumuna dayanan basit bir Pİ geliştirildi. ST metodunda üç değişken
belirlendi ve bunlar HER2/neu, aksiller nodal durum ve östrojen reseptör durumu idi. Nüksü belirleyen en önemli
faktör aksiller nodal durum idi.
Sonuç: ST ve Cox regresyon analizi ile elde edilen Pİ’ler, hastalıksız sağkalımın tahmin edilmesinde benzer performans
gösterdi. Modellerin hata oranlarının, train ve test setlerinde birbirilerine yakın olduğu belirlendi. Ayrıca HER2/neu
ve aksiller nodal durumun, meme kanserli hastalarda hastalıksız sağkalım süresinin tahmini için en önemli faktörler
olduğu belirlendi.
Anahtar sözcükler: Meme kanseri, prognostik indeks, sağkalım ağacı, recursive partitioning, hastalıksız sağkalım

Introduction
In general, 5-year disease-free survival (DFS)
ranges from 65% to 80% in all populations in breast
cancer patients (1). Current evidence supports a
clear association between some clinicopathologic
factors and reduced DFS. The clinicopathologic
characteristics of patients are heterogeneous, and the
survival times are different in subgroups of patients.
The aim of prognostic classification indexes is to define
subgroups of patients with well-separated survival
distributions. Combinations of prognostic factors
further augment the recurrence risk, warranting the
recommendation of combination chemotherapy and
radiotherapy to improve survival. Several prognostic
classification indexes were developed (2-5), but often
these are contradictory.
The Cox regression analysis is the most common
tool for investigating simultaneously the influence of
several factors on the survival time of patients (6).
However, it does not provide an estimate of the degree
of separation of the different subgroups. Decision
tree algorithms such as the survival tree (ST) method
allow for nonlinear relations between predictive
factors and outcomes. They also support mixed
(numerical and categorical) and heterogeneous data
types, isolate outliers, and incorporate a pruning
process using cross-validation as an alternative to
testing for unbiasedness with a second data set (7,8).
They can identify prognostic subgroups that are
clinically useful because they are based on simple
combinations of clinical characteristics. In contrast
to traditional regression methods, which compute a
prognostic index as a weighted average of the patient’s
characteristics (i.e. an algebraic formula), decision
tree algorithms construct groups based on logical
combinations of patient characteristics. Thus, the
770

prognostic subgroups are based directly rather than
indirectly on the patient characteristics. Therefore,
decision tree methods such as ST are more suitable
than classical statistical methods. In the literature,
there are several reports about the separation of
patients with different prognoses for survival into
subgroups (5,9-12).
The purpose of this study was to determine 2
different prognostic indexes for the differentiation
of subgroups of nonmetastatic breast cancer
patients and to explore the very complicated and
heterogeneous survival data with the Cox regression
analysis and ST methods.
Materials and methods
Patients
A retrospective analysis was performed in 640
breast cancer patients diagnosed between 1997 and
2006. Data for 410 nonmetastatic patients were
available and formed the basis of this study. We
investigated age, menopausal status, age of menarche,
body mass index, hormone replacement therapy,
pathology of tumor, quadrant of tumor, tumor size,
estrogen and progesterone receptor status (Lab Vision,
USA), histologic and nuclear grading according
to Scarf-Bloom-Richardson criteria (13), axillary
nodal status, lymphovascular invasion, HER2/neu
expression (NeoMarkers, USA), adjuvant radiotherapy,
chemotherapy, and hormonal therapy as prognostic
factors. Surgery (modified radical mastectomy or
breast-conserving surgery) was the primary local
treatment. According to the American Joint Committee
on Cancer staging (14), 13 (3.2%) patients had in situ,
319 (77.8%) had early stage, and 78 (19%) had locally
advanced disease. Tumors were considered positive for
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estrogen and progesterone receptors if more than 10%
of the tumor cells showed nuclear staining (15). HER2/neu staining was scored on a scale of 0, 1+, 2+, or
3+. Scores of 0 or 1+ were deemed negative for HER2/neu. Positive HER-2/neu expression was defined by
weak/moderate (2+) or moderate/strong (3+) complete
membrane staining in more than 10% of the tumor
cells (16). Samples with scores of 2+ were assessed
further by fluorescence in situ hybridization (FISH)
analysis to examine gene amplification. FISH analysis
was performed using the PathVysionTM HER-2 DNA
Probe Kit Package Insert (Vysis Inc., Illinois, USA)
according to the manufacturer’s instructions, using
reagents, probes, and positive controls provided by the
manufacturers (17). Adjuvant radiotherapy was given to
286 (69.8%) patients, chemotherapy was administered
to 334 (81.5%) patients, and hormonal therapy was
given to 313 (76.3%) patients. Chemotherapy was
delivered prior to radiotherapy. Hormonal therapy
was initiated after the completion of radiotherapy and
typically continued for 5 years in hormone receptorpositive patients until the recurrence of disease.
Follow-ups consisted of a clinical assessment every 3
months for the first 2 years, every 6 months for 3 years,
and annually after 5 years.
Statistical analysis
Descriptive statistics of clinical and pathologic
data for the entire patient population are listed in
Table 1. We performed classical statistical analysis
to examine the differences in the distribution of
variables between patients who had a recurrence and
those who did not. The Kolmogorov-Smirnov test was
used to assess the normality of numeric variables. For
all of the numeric variables that were nonnormally
distributed, comparison between the 2 groups was
made by the Mann-Whitney U-test, and results were
expressed as medians and interquartile ranges (IQR).
Association of recurrence with nominal variables
was assessed using the chi-square test.
Before the building of the models, the data sets
were randomly split into 2 subsets: 70% (n = 287)
of the data for the training set and 30% (n = 123)
of the data for test set. Using ST and Cox regression
analysis, 2 different prognostic indexes, which were
solely based on standard factors, were developed.
Harrell’s concordance index was computed for both
the training and test sets.

Survival analysis was performed for DFS, the time
from initial diagnosis (initiation of the first treatment)
to the first recurrence of disease (locoregional
recurrence, distant metastases, or second cancer).
For the terminal nodes of the ST and the Cox model
from the training data set, the difference between the
curves was estimated by the Kaplan-Meier method,
and the curves were evaluated with the log-rank test,
also known as the Mantel-Cox test. Follow-up time
for each patient was calculated in months from the
last day of the initial treatment to the date of death or
the date of last visit. For all statistical tests, P-values
less than 0.05 were considered significant.
Tree-structured survival analysis: recursive
partitioning analysis
The recursive partitioning analysis is used to
correctly classify members of a population based on
categorical or continuous dependent variables (18).
It is commonly used for classification and regression
problems. It is also used as an approach for extending
regression trees to survival data; the prediction at each
leaf is a survival distribution (19,20). The goal is to
produce subsets of the data that are as homogeneous
as possible with respect to survival. In our study,
tree-structured survival analysis was called survival
tree (ST) for recursive partitioning analysis. For
analyzing survival data, deviance-based criteria that
need survival distribution with just one parameter
varying between nodes is used for splitting. This
approach evaluates all possible dichotomous splits
for all potential prognostic factors (19). In ST, the
recursive partitioning procedure commonly uses
exponential scaling as the splitting rule. To find a tree
that is defined by characteristics of the underlying
population, the tree is pruned. ST uses a complexity
parameter (cp) for the control of tree-growing.
Breiman et al. (18) presented a comprehensive
overview of recursive partitioning methodology.
Cox regression analysis
Survival analysis investigates the relationship
of the survival distribution to covariates. Most
commonly, this examination entails the specification
of a linear-like model for the log hazard. The Cox
regression analysis may be written as:
h(t, ×) = h0(t)eβ´×,
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where x is the covariate vector, β is the unknown
parameter vector, and h0(t) is the baseline hazard
(i.e. the hazard for the respective individual when all
independent variable values are equal to zero). The
resultant hazard is denoted as h(t, ×), given the values
of the m covariates for the respective case and the
respective survival time (t).
The Cox regression analysis equation has 2
assumptions, while no assumptions are made about
the shape of the underlying hazard function. The
first assumption is that a multiplicative relationship
between the underlying hazard function and the
log-linear function of the covariates is specified.
The second assumption is that there is a log-linear
relationship between the independent variables and
the underlying hazard function (6).
Harrell’s concordance index
Harrell’s concordance index is a measure of survival
performance. It does not depend on choosing a fixed
time for evaluation of the model and specifically
takes into account the censoring of individuals. The
error rate is computed as 1-C, where C is Harrell’s
concordance index. Error rates are between 0 and 1,
with 0.5 corresponding to a procedure with results
no better than random. A value of 0 denotes perfect
accuracy (21,22).
We used Harrell’s concordance index to quantify
the accuracy of ST and Cox regression analysis.
Kaplan-Meier survival analysis
The Kaplan-Meier analysis is a nonparametric
technique for estimating time-related events (23).
It can be used to test the statistical significance of
differences between survival curves associated with 2
different circumstances. It is applied by analyzing the
distribution of patient survival times following their
recruitment to a study. The analysis expresses these in
terms of the proportion of patients still alive up to a
given time following recruitment. In graphical terms,
a plot of the proportion of patients surviving against
time has a characteristic decline (often exponential),
the steepness of the curve indicating the efficacy of
the treatment being investigated. The more shallow
the survival curve, the more effective the treatment
(24).
A variety of tests may be used to compare 2 or
more Kaplan-Meier curves under certain well772

defined circumstances. Median remission time (the
time when 50% of the cohort has reached remission),
as well as quantities such as 3-, 5-, and 10-year
probability of remission, can also be generated from
Kaplan-Meier analysis, provided that there has been
sufficient patient follow-up.
Results
Characteristics of study subjects
After a median follow-up of 48 months, 100
(24.4%) patients had at least 1 DFS event. Tumor
size, quadrant of tumor, nuclear and histologic
grade, estrogen and progesterone receptor status,
lymphovascular invasion, axillary nodal status, and
HER2/neu were statistically significant prognostic
factors for recurrence (Table 1). The median age was
50 years (mean of 51, range of 26-79), and the median
tumor size was 3 cm (mean of 3.16, range of 0.1-14).
Cox regression analysis for the prediction of
DFS in breast cancer patients
In Table 2, we give estimates of the regression
coefficients in the stepwise Cox regression analysis
for the training data set. In this analysis, HER2/
neu status and axillary nodal status have significant
effects as prognostic factors (P < 0.001 and P < 0.01,
respectively). Interaction terms did not enter the final
model. Based on these results, we propose the simple
prognostic index (PI):
PI = HER2/neu status + axillary nodal status,
where axillary nodal status and HER2/neu note
the indicator function taking values of 0 and 1,
dependent on whether the patient is axillary nodal
status = positive or HER2/neu status = positive,
respectively. The index gives from 0 to 2 points to
each patient (Table 3). PI = 0 is the group with the
minimal risk, while PI = 2 is the group with the
maximum risk.
The concordance error rate of this model was
0.2093 for the training set and 0.2160 for the test set
(Table 4).
ST for the prediction of DFS in breast cancer
patients
With the ST method, we identified 3 variables
that play important roles in explaining recurrences:
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Table 1. Clinicopathologic characteristics of the study groups.
Recurrence
Independent variables

P-value
Absent

Present

Age (years) median (IQR)

50 (15)

51 (16)

0.409

Age of menarche (years) median (IQR)

13 (1)

13 (2)

0.707

2.75 (2.1)

3 (2.8)

0.019

29 (5.9)

30 (7.1)

0.320

n (%)

n (%)

Tumor size (cm) median (IQR)
Body mass index (kg/cm2) median (IQR)

Hormone replacement therapy

Present
Absent

53 (18.1)
240 (81.9)

14 (15.1)
79 (84.9)

0.606

Menopausal status

Post
Pre

160 (51.6)
150 (48.4)

49 (49.0)
51 (51.0)

0.649

Quadrant of tumor

Unicentric
Multicentric

288 (94.4)
17 (5.6)

81 (85.3)
14 (14.7)

0.007

Nuclear grade

I + II
III

177 (76.0)
56 (24.0)

47 (58.8)
33 (41.3)

0.005

Histologic grade

I + II
III

191 (70.0)
82 (30.0)

50 (54.9)
41 (45.1)

0.009

Estrogen receptor status

Negative
Positive

67 (22.4)
232 (77.6)

40 (42.1)
55 (57.9)

<0.001

Progesterone receptor status

Negative
Positive

78 (26.0)
222 (74.0)

35 (36.8)
60 (63.2)

0.042

Adjuvant radiotherapy

Absent
Present

87 (28.1)
223 (71.9)

37 (37.0)
63 (63.0)

0.091

Chemotherapy

Absent
Present

62 (20.0)
248 (80.0)

14 (14.0)
86 (86.0)

0.232

Lymphovascular invasion

Absent
Present

154 (55.6)
123 (44.4)

32 (36.8)
55 (63.2)

0.002

Axillary nodal status

Negative
Positive

200 (64.5)
110 (35.5)

40 (40.0)
60 (60.0)

<0.001

Pathology

Ductal
Nonductal

240 (77.4)
70 (22.6)

81 (81.0)
19 (19.0)

0.538

HER2/neu

Negative
Positive

278 (89.7)
32 (10.3)

56 (56.0)
44 (44.0)

<0.001
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Table 2. Estimated regression coefficients with standard error hazard ratios with 95% (CI) intervals and
P-values from the stepwise Cox model with forward elimination for disease-free survival time.
Independent variables

β

SE

HR

95% (CI)

p

Axillary nodal status

Negative (0)
Positive (1)

0
1.763

0.51

1
5.83

(2.14-15.84)

<0.01

HER2/neu

Negative (0)
Positive (1)

0
1.572

0.43

1
4.82

(2.09-11.09)

<0.001

SE: Standard error
HR: Hazard ratio
Table 3. Subgroups for prognostic index (PI) of Cox model.
Group

Value

Subgroup categories

COX-I

PI = 0

HER2/neu (negative) + axillary nodal status (negative)

COX-II

PI = 1

HER2/neu (negative) + axillary nodal status (positive)
HER2/neu (positive) + axillary nodal status (negative)
COX-III

PI = 2

HER2/neu (positive) + axillary nodal status (positive)

Table 4. Subgroups for prognostic index of ST.
Group

Node

Terminal node

ST-I

4

Axillary nodal status (negative) + HER2/neu (negative)

ST-II

5

Axillary nodal status (negative) + HER2/neu (positive)

ST-III

12

Axillary nodal status (positive) + HER2/neu (negative) + estrogen receptor status (positive)

ST-IV

13

Axillary nodal status (positive) + HER2/neu (negative) + estrogen receptor status (negative)

ST-V

7

Axillary nodal status (positive) + HER2/neu (positive)

axillary nodal status, HER2/neu status, and estrogen
receptor status (Table 4). This indicated that the
axillary nodal expression status was the most
important determining factor for recurrence. This
first-level split produced the 2 initial branches of the
tree, negative versus positive. We could see differences
in the 2 subtrees. For the axillary nodal status positive
and negative subgroups, HER2/neu proved to be the
best predicting variable. For the positive axillary
nodal status and the negative HER2/neu branch,
estrogen receptor status (negative vs. positive) was
774

the most prominent predicting variable. The ST has 8
leaf nodes, 5 of which are terminal nodes.
The concordance error rates of this model were
0.1899 for the training set and 0.2143 for the test set
(Table 5).
Survival analysis for breast cancer patients
In the Cox regression analysis, the 5-year DFS rate
was 78.0% in the entire patient population. For the
COX-I (PI = 0) subgroup, which included patients
with HER2/neu and axillary nodal status negative,
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Table 5. Harrell’s concordance error rates (C index) for methods.
Training set

Test set

Method
C index

SD

C index

SD

COX

0.2093

0.0758

0.2160

0.1062

ST

0.1899

0.0812

0.2143

0.0855

the 5-year DFS rate was 93.3%. Median survival
was 259.0 in this subgroup. For the COX-II (PI = 1)
subgroup with HER2/neu positive and axillary nodal
status negative or HER2/neu negative and axillary
nodal status positive, the 5-year DFS rate was 67.2%.
Finally, for the COX-III (PI = 2) subgroup with
HER2/neu positive and axillary nodal status positive,
the rate was 50.0% (Table 6). Figure 1 shows the
estimated DFS rates according to the Cox regression
analysis. The statistical significance of the difference
between the survival curves of the subgroups was
tested using the log-rank test (Table 7). All of the
survival curves of the subgroups were statistically
different from each other. The survival distributions
for the Cox regression analysis were statistically
significant (χ2 = 107.319, df = 2, P < 0.001).
In the ST method, the 5-year DFS rate was 78.0%
in the entire patient population. For the terminal
node of ST-I with HER2/neu and axillary nodal
status negative, the 5-year DFS rate was 93.3%.
Median survival was 259.0 in this subgroup. For the
ST-II subgroup with axillary nodal status negative
and HER2/neu positive, it was 42.9%. For the STIII subgroup with axillary nodal status positive,

Table 7. Pairwise comparisons by log-rank for PI obtained from
Cox model.

COX-I

COX-II

COX-III

χ2 = 88.116
P < 0.001

χ2 = 81.047
P < 0.001
χ2 = 7.631
P = 0.006

COX-II

HER2/neu negative, and estrogen receptor status
positive, it was 78.8%. For the ST-IV subgroup with
axillary nodal status positive, HER2/neu negative,
and estrogen receptor status negative, it was 45.4%.
Finally, for the ST-V subgroup with axillary nodal
status and HER2/neu positive, it was 50.0% (Table
8). Figure 2 shows the estimated DFS rates according
to the ST method. The statistical significance of the
difference between the survival curves of 2 terminal
nodes was tested using the log-rank test (Table 9).
In the ST method, ST-I was statistically different
from all other subgroups. The survival curve of
ST-V was statistically different from ST-I and ST-

Table 6. Descriptive statistics and 5-year disease-free survival (DFS) for Cox model.

Group

Median

Mean

Standard error

Number of
recurrences

n

5-year DFS
(%)

COX-I

259.0

228.1

16.6

9

135

93.3

COX-II

47.8

49.5

4.5

42

128

67.2

COX-III

29.3

31.9

3.0

12

24

50.0

Total

139.3

159.2

14.5

63

287

78.0
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0.9

0.9

0.8

0.8

0.7

0.7

Diseasefree Survival

Diseasefree Survival

Developing and comparing two prognostic indexes in breast cancer patients

0.6
0.5
0.4
COX-I

0.6
0.5
ST-I

0.4

0.3

0.3

0.2

0.2
0.1

0.1
COX-III

0.0
0

50

100

COX-II

ST-V

0.0

150
200
Time (months)

250

0

300

Figure 1. Kaplan-Meier survival curves of the 3 groups generated
from the Cox model.

ST-II

50

ST-IV ST-III
100
150
200
Time (months)

Median

Mean

Standard error

Number of
recurrences

n

5-year DFS
(%)

ST-I

259.0

228.1

16.6

9

135

93.3

ST-II

42.2

40.5

4.0

12

21

42.9

ST-III

50.7

60.4

11.3

18

85

78.8

ST-IV

47.8

45.7

6.9

12

22

45.5

ST-V

29.3

31.9

3.1

12

24

50.0

Total

139.3

159.2

14.5

63

287

78.0

Table 9. Pairwise comparisons by log-rank for PI obtained from ST.

ST-I
ST-II
ST-III
ST-IV

776

300

Figure 2. Kaplan-Meier survival curves of the 5 groups (terminal
nodes) generated from ST.

Table 8. Descriptive statistics and 5-year disease-free survival (DFS) for each node of ST.

Group

250

ST-II

ST-III

ST-IV

ST-V

χ2 = 95.764
P < 0.001

χ2 = 42.634
P < 0.001

χ2 = 82.791
P < 0.001

χ2 = 81.047
P < 0.001

χ2 = 1.845
P = 0.174

χ2 = 0.182
P = 0.670

χ2 = 3.601
P = 0.058

χ2 = 1.522
P = 0.217

χ2 = 7.752
P = 0.005
χ2 = 1.793
P = 0.181
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III. The survival distributions for the ST method
were statistically significant (χ2 = 116.215, df = 4, P
< 0.001).
According to these findings, we determined that
COX-I was the group with the low risk, COX-II was
the group with the intermediate risk, and COX-III
was the high-risk group for DFS. For the ST groups,
we determined that ST-I was the group with the
low risk, ST-III and ST-IV were the groups with the
intermediate risk, and ST-II and ST-V were the highrisk groups for DFS.
Discussion
Based on the observation of 410 patients over a
median follow-up of 48 months, we determined 2
different prognostic indexes for the differentiation
of subgroups of breast cancer patients using ST and
Cox regression analysis methods. As a result of Cox
regression analysis, we proposed the simple PI, which
is a sum of HER2/neu status and axillary nodal status.
In the ST method, we identified 3 variables that played
important roles in explaining recurrences: HER2/neu
status, axillary nodal, and estrogen receptor status.
We found that the PI of Cox regression analysis and
ST based on recursive partitioning analysis had a
similar performance for prediction of DFS in breast
cancer patients.
Breast cancer is a heterogeneous disease
that encompasses several distinct entities with
remarkably different biological characteristics and
clinical behavior. Currently, lymph node metastases,
tumor grade and size, and expression of hormone
receptors provide the only true prognostic and
predictive factors related to clinical outcome and
response to treatment, respectively. Many other
potential candidates have been suggested, but due to
their limited predictive power have not been widely
accepted by the general oncologic community.
These histopathological features do not allow us any
insight into breast cancer biology, however, and these
prognostic classifications are far from perfect. With
the development of genetic and molecular techniques,
new molecular classifications and therapeutic targets
for breast cancer have been suggested (25,26). The
amplification and overexpression of HER2/neu is
an established prognostic factor in patients with

breast cancer (27,28). In 81 studies considering
27,161 patients, 90% of the studies and 92% of the
cases found that HER2/neu overexpression predicted
breast cancer outcome, both in univariate and
multivariate analysis (29).
For the development of different prognostic
classification indexes, we used 2 different statistical
approaches. The first was based on a multivariate
analysis of the prognostic factors of our study with
the well-known Cox regression analysis. With this
approach, we identified HER2/neu status and axillary
nodal status as relevant prognostic factors upon which
the classification index is based. In primary operable
breast cancer, the Nottingham Prognostic Index (NPI),
based on tumor size, lymph node stage, and histological
grade, can identify 3 prognostic groups with 10-year
survival rates of 83%, 52%, and 13% (30). The index
defined a subset with better survival than could be
defined individually by each of its 3 components,
but it did not succeed in defining a subset with
survival similar to expectations. Therefore, additional
prognostic factors are needed. In the Cox regression
analysis from the present study, the 3 resulting
prognostic groups show a very good separation with
5-year DFS rates of 93.3%, 67.2%, and 50.0%.
The second statistical approach makes use of the
decision tree method (7,18,31), in which prognostic
groups are obtained through subsequent splitting
according to the most important factors. The risk
groups resulting from this procedure are defined by
HER2/neu status, axillary nodal status, and estrogen
receptor status. The resulting 5 prognostic groups
show a very good separation with 5-year DFS rates of
93.3%, 42.9%, 78.8%, 45.5%, and 50.0%. The longest
surviving terminal node, ST-I, included HER2/
neu and axillary nodal status negative patients. The
shortest surviving terminal node, ST-V, included
HER2/neu and axillary nodal status positive patients.
HER2/neu expression status and axillary nodal status
were the most important determining factors for
recurrence. The HER2/neu-overexpressed subgroups
had the shortest DFS of the 2 methods. The PI of
the ST and Cox regression methods, which may be
explained by using different prognostic indexes, had
similar performances in predicting DFS, and the
error rates of the models were close to each other in
the training and test sets.
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Both of the resulting prognostic groups of our
classification methods lead to a seemingly good
separation of the nonmetastatic breast cancer
patients. However, validation of these results in other
studies is absolutely necessary before a definitive
judgment can be made. Prognostic classification
indexes are based on standard prognostic factors,
which are suitable for routine use in the clinic as the
basis of rational treatment decisions. In the ninth
St. Gallen expert consensus meeting in 2005, the
panel divided patients into low-, intermediate-, and
high-risk categories (32). Tumor size, axillary nodal
status, age, and grade were the main features used to
define risk categories. The panel also added 2 features
not previously accepted as sufficiently reliable to
define risk category. The first was overexpression or
amplification of the HER2/neu oncogene and the
second was peritumoral vessel invasion, especially
lymphovascular invasion (33). These categories did
not change at the 10th annual St. Gallen meeting (34).
In our study, although lymphovascular invasion and
HER2/neu were statistically significant prognostic
factors for recurrence (Table 1), only HER2/neu
expression status was established as a prognostic
factor for recurrence in the 2 methods.
The analyses conducted in this study demonstrated
that the ST method for segregating patients into
groups with similar clinical features and survival
consistently applied the variables reported to be
important in the Cox regression analysis. The fact
that each of these approaches used similar clinical
variables to stratify patient survival confirms their
clinical importance and supports the validity of the
ST analysis. Lamborn et al. (12) evaluated several
potential prognostic markers for survival of patients
with glioblastoma multiforme in order to establish
risk groups by using Cox regression and recursive
partitioning analyses. They reported that recursive
partitioning is an exploratory tool that has found
favor in recent years because it provides a method
of categorizing patients into risk groups. Kenneth
et al. (9) reported that clinicians often experience
difficulty applying standard statistical methods to
assess the interactions between clinical variables,
determine the cumulative effect of these variables
on survival, and translate this information into
appropriate management, because of the complex
presentations of patients with unknown primary
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carcinoma (UPC). To address the problem they
explored C&RT analysis, and they showed that
C&RT is a simple method for dissecting complex
clinical issues in UPC patients. However, before
accepting this model, they advised validation studies
on an independent data set.
Ture et al. (11) tried to discover the risk groups
and make decision rules for the management of breast
cancer by using the C&RT, CHAID, QUEST, ID3,
C4.5, and C5.0 methods and Cox regression analysis.
They also determined new prognostic indexes for the
differentiation of subgroups of breast cancer patients
with models for risk factors according to KaplanMeier analysis and evaluated the performance of
the methods using random survival forests (35).
Ture et al. (35) further analyzed different decision
tree methods (C&RT, CHAID, QUEST, C4.5, and
ID3) and used them in addition to the well known
Kaplan-Meier estimates to investigate the predictive
power of these methods. In nonmetastatic breast
cancer patients, they found that the C4.5 method
showed a better degree of separation for predicting
survival. They recommended using decision tree
methods together with Kaplan-Meier analysis in
order to determine risk factors and the effect of these
risk factors on survival.
The German Breast Cancer Study Group (5)
validated the C&RT method with Cox regression
analysis and the NPI. They reported that the C&RT
method showed a better degree of separation in node
negative breast cancer patients, and that a young age
(≤40 years) and very high estrogen receptor values
were associated with a worse prognosis. Although
the 5-year survival rates demonstrate that C&RT and
Cox regression analysis lead to a better separation
than the NPI, they stressed that such an assessment
is difficult as they used more groups (3 for Cox, 4
for C&RT) than the NPI, which resulted in smaller
groups. The current study used 3 groups for Cox and
5 groups for ST.
The ST and Cox regression methods had similar
performances in predicting DFS. However, validation
through other independent studies is necessary
before a definitive judgment can be made. Future
clinical trials of patients with breast cancer should
prospectively examine the ability of the prognostic
information obtained from both methods to facilitate
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precise clinical decision-making. Furthermore, ST is
a suitable method for exploring relationships hidden
within heterogeneous data sources as a result of treestructured survival analysis. These data can be used

to identify relatively homogeneous breast cancer
patient populations with similar survival in order to
analyze novel therapeutic interventions and tailor
treatment for individual breast cancer patients.
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